Evidence map›Paper›PMID 34623971›Full record

ArticleAging2021

Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer.

Xuhui Fan, Haotian Fu, Ni Xie, Hangcheng Guo, Tiantian Fu, Yunfeng Shan

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Network pharmacology andWorld journal of gastroenterology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Role of STAT3 in pancreatic cancer.Exploration of targeted anti-tumor therapy · 2024
    Review
  11. International journal of molecular sciences · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xuhui FanThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Haotian FuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Ni XieDepartment of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Hangcheng GuoThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Tiantian FuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Yunfeng ShanThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
First Affiliated Hospital of Wenzhou Medical University · CNShanghai First People's Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death with the characteristics of chemoresistance and early metastasis. Panaxadiol, a triterpenoid saponin extracted from the roots of American ginseng, has been proved to display anti-tumor activity in colon cancer. In this study, we found panaxadiol significantly inhibited proliferation, and induced apoptosis in human pancreatic cancer cell lines PANC-1 and Patu8988 in a dose-dependent manner. Furthermore, the expression of apoptosis-related proteins (Bax, Bcl2, Cleaved-caspase3) was detected via western blot and immunofluorescence staining. In addition, panaxadiol was also found to inhibit the migration of pancreatic cancer cells by wound healing and transwell assays.

Indexed as

Cell Line, TumorCell ProliferationGinsenosidesHumansJanus Kinase 2Models, MolecularMolecular StructurePancreatic NeoplasmsSignal TransductionSTAT3 Transcription FactorGinsenosidesJAK2 protein, humanJanus Kinase 2panaxadiolSTAT3 protein, humanSTAT3 Transcription FactorapoptosisJAK2-STAT3panaxadiolpancreatic cancerproliferation

Identifiers

PMID34623971
PMCPMC8544303
OpenAlexW3203603584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.